WV HB4626

Establishes a grant program administered by the Secretary of Health to fund FDA drug development trials for ibogaine as a treatment for opioid use disorder, co-occurring substance use disorders, and other neurological or mental health conditions

Requires grant applicants to be corporate entities with capacity to conduct FDA trials, submit detailed trial designs including cardiac safety protocols, and provide plans for establishing corporate presence in West Virginia

Creates a selection committee composed of subject matter experts, philanthropic partners, and legislative designees to review applications and recommend candidates to conduct the trials

Mandates selected applicants submit an Investigational New Drug (IND) application to the FDA and seek breakthrough therapy designation under 21 U.S.C. Section 356

Requires applicants to match state funding dollar-for-dollar and trial sites must be equipped with cardiac intensive care capabilities